Second NJ Trial Underway In Novartis Bone Drug Litigation

Law360, New York (April 26, 2013, 9:54 PM EDT) -- Novartis Pharmaceuticals Corp. failed to adequately warn cancer doctors that its bone drug Zometa could cause osteonecrosis in patients' jaws, despite ample links between the medication and bone death, attorneys for a woman suing Novartis contended Friday in the second trial for the New Jersey mass tort litigation.

Counsel for Beverly Meng and Novartis gave jurors vastly different pictures of the company's actions during opening statements in the second case to go to trial in multicounty litigation in the state over Zometa and its less potent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.